This supports the notion that potential protein substrates such as CD45 68, CD43 or CD44 in MLL-r cells could undergo site-specific O-glycosylation events that are absent in normal BCP cells and which could be used as a leukemia-specific marker or target for treatment. The gene discussed is KMT2A; the disease is leukemia.